NEW YORK, March 30 (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators ...

November 18, 2010 — The prostate cancer vaccine sipuleucel-T (Provenge, Dendreon) received a middling vote of confidence for its on-label use and what amounted to a thumbs-down vote for its off-label ...

Suddenly, the range of options for prostate cancer patients has expanded. The latest major event came Sept. 9 when a phase three clinical trial was opened up so the patients on placebo could get the ...

announced today that four abstracts featuring PROVENGE^® (sipuleucel-T) data from ongoing Phase II sequencing studies and the PROCEED registry, and two abstracts highlighting preliminary Phase II data ...

WASHINGTON - Medicare officials confirmed Thursday that the program will cover the $93,000 price tag for prostate-cancer drug Provenge, an innovative therapy that typically gives men suffering from an ...

Dendreon filed for bankruptcy protection on Monday after sales of Provenge fell way short of expectations and the company could not pay off a huge debt coming due. By Andrew Pollack Costly treatments ...

A new model that compares costs and outcomes of drugs used in the treatment of castrate-resistant prostate cancer has concluded that generic docetaxel and abiraterone (Zytiga) offer better value than ...

Biotechnology company Dendreon Corp. said it received a letter from the Securities and Exchange Commission regarding an informal inquiry over clinical trials for the prostate cancer vaccine candidate ...